Bumetanide in heart failure in infancy.

  title={Bumetanide in heart failure in infancy.},
  author={O. C. Ward and L. Lam},
  journal={Archives of Disease in Childhood},
  pages={877 - 882}
The effect of bumetanide in infants with congenital heart disease presenting with cardiac failure was studied. The study was divided into acute (3 days) and long-term (mean 10.5 weeks) cases. A total of 12 male infants was included in the acute study and 13 cases were evaluated in the long-term study. The dose used in the acute study (0.015 mg/kg) was suboptimal; notwithstanding it was found to cause significant natriuresis and chloruresis. Bumetanide in doses varying in different infants from… Expand
The use of bumetanide for oliguric acute renal failure in preterm infants*
Bumetanide therapy significantly increased urine output within 24–48 hrs, but its use was associated with a transient increase in serum creatinine level, which can be used in preterm infants to reverse oliguria when therapy with furosemide fails. Expand
Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.
Bumetanide is a potent 'loop' diuretic for the treatment of oedema associated with congestive heart failure, hepatic and renal diseases, acute pulmonary congestion and premenstrual syndrome and inExpand
Pharmacokinetics and Pharmacodynamics of Bumetanide in Critically Ill Pediatric Patients
Plasma concentrations of bumetanide accurately predicted several renal effects using a link model with similar pharmacodynamic parameters in each case, and caused significant increases in the excretion rate of urine and each measured electrolyte. Expand
Bumetanide: A New Loop Diuretic (Bumex, Roche Laboratories)
Bumetanide has demonstrated efficacy in the management of edema associated with congestive heart failure, hepatic cirrhosis, and renal insufficiency and has demonstrated an adverse-reaction profile similar to that of furosemide, although the incidence of hypochloremia and hypokalemia is greater with bumetanides. Expand
Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation.
Nine term neonates treated with extracorporeal membrane oxygenation received bumetanide to treat volume overload, and significant diuresis, natriuretic, and kaliuresis were observed, although the duration of these effects was less than expected given the prolonged renal elimination of bumetAnide. Expand
Mineral excretion following furosemide compared with bumetanide therapy in premature infants
Mineral excretion following single doses of furosemide were compared with bumetanide in a random cross-over trial in 17 premature infants. The mean birth-weight and gestational age were 889±85 g andExpand
Diuretic therapeutics in the pediatric patient.
The available data concerning the ontogeny of renal function and the attempts to apply diuretic therapy to pediatric disease are reviewed and it is concluded that results obtained to date suffer from the absence of a rigorous attempt to answer the fundamental therapeutic questions. Expand
Pharmacology, Therapeutic Efficacy, and Adverse Effects of Bumetanide, A New “Loop” Diuretic
Bumetanide is a recently developed natriuretic and diuretic agent, belonging to the “loop” class of diuretics. Since it is rapidly and almost completely absorbed after oral administration, oral andExpand
The pharmacology and therapeutics of diuretics in the pediatric patient.
  • T. Wells
  • Medicine
  • Pediatric clinics of North America
  • 1990
Well-designed clinical trials in neonates, infants, and younger children are necessary prerequisites to safer and more efficacious diuretic therapy, especially in premature neonates. Expand
Novel medications for neonatal seizures: Bumetanide and topiramate
Bumetanide and topiramate are two novel AEDs that have mechanisms of action uniquely suited to suppressing seizures in the newborn brain, with promising basic science data supporting their use in human newborns. Expand


Frusemide in heart failure of infancy
Frusemide was found to be a safe effective diuretic in infants with heart failure, resulting in clinical improvement, marked excretion of water, sodium, and chloride, with a lesser and more variable effect on potassium excretion. Expand
Bumetanide, a new potent diuretic. A clinical evaluation in congestive heart failure.
Bumetanide is very well tolerated and is one of the most potent diuretics available to-day, and has apparently a site of action in the ascending limb of the loop of Henle. Expand
Renal action, therapeutic use, and pharmacokinetics of the diuretic bumetanide
The diuretic activity of bumetanide has been studied in 16 normal subiects and 40 hospitalized patients with fluid retention and indicated that despite rapid renal drug clearance, a substantial part of infected drug left the “central” compartment by one or more extrarenal routes. Expand
Bumetanide: Potent New “Loop” Diuretic
Bumetanide, a pharmacologically new diuretic, was evaluated in 27 subjects and produced effective diuresis with minimal alteration in biochemical and haematological status and the only adverse effect was gastric discomfort in one patient. Expand
The sites of action of bumetanide in man.
It was a very potent diuretic, as judged by the fact that, at peak effects during water diuresis, 20% of filtered sodium was excreted in the urine, indicating a major site of action on the ascending limb of the loop of Henle. Expand
Magnesium Deficiency in Patients on Long-Term Diuretic Therapy for Heart Failure
Clinical features consistent with the presence of magnesium deficiency were found in all five magnesium-deficient patients and these features were, with few exceptions, corrected by magnesium replacement. Expand
Heart failure in the newborn infant
Heart failure in the newborn infant is characterized by tachypnea, tachycardia, feeding difficulties, pulmonary râles and rhonchi, hepatic enlargement, and cardiomegaly, which is less common than in the older child or adult. Expand
Sustained Hyperglycaemia in Pregnancy
SIR,-May I draw your attention to an error in the leading article on "Benign Forms of Multiple Sclerosis" (12 February, p. 392) where it states: "In 1959 McAlpine and N. Compston surveyed 241 casesExpand
Effect of Frusemide Administration on Calcium Excretion
Each of eight adipose but otherwise normal patients on a reducing diet received daily oral doses of frusemide for four days; the degree of hypercalciuria was found to be significant during the firstExpand
Acute Perforated Peptic Ulcer
The factors which may have contributed to the considerable fall in mortality during that time are discussed, and a comparative analysis of the mortality in recent years show a uniform decrease in Great Britain, America, and Scandinavia. Expand